NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Autem Therapeutics

Autem Therapeutics

Private
Hanover, New HampshireHealthcare & Life Scienceshttps://www.autemtherapeutics.com/

Last Round

Series A

Extension

Jun 6, 2022

Total Funding Raised

$14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Autem Therapeutics is an oncology and bioelectric technology company developing a non-invasive, non-toxic treatment platform for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

bioelectric medicinenon-invasive cancer treatmenttumor treating fieldsbioelectric oncologyelectromagnetic field therapypersonalized oncologyHepatocellular CarcinomaHCCsolid tumor treatmentmedical devicemedtechGlioblastomaGBMFDA breakthrough designationAI in oncologyclinical stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autem Therapeutics Comparables

Compare Autem Therapeutics with similar companies based on industry and business-model similarity.

Autem Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TheraBionic
86%
EMulate Therapeutics
85%
QV Bioelectronics
82%

Autem Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJun 6, 2022

Key People

Founding team and executive leadership

Frederico Perego Costa

Founder & Chief Scientific Officer

Founding Team

Michael Choukas

Co-founder And Chief Executive Officer

Founding Team

Autem Therapeutics Investors

Notable investors and investment history

Autem Therapeutics investors
InvestorRounds
Zentynel Frontier InvestmentsSeries A Extension
Spectra InvestimentosSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 203% MoM.

  • Nov 8, 2025

    Monthly visitors increased 527% MoM to 2.1K.

Autem Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Autem Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Autem Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHanover, New Hampshire
Employee Range15
Year Founded2017
Last FundingJun 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.